Astrazeneca News

AstraZeneca's breast cancer drug, Etcamah, failed to meet its primary goal in a late-stage trial, despite receiving U.S. approval for advanced breast cancer a w

AstraZeneca's breast cancer drug, Etcamah, failed to meet its primary goal in a late-stage trial, showing only a numerical improvement when combined with palboc

The US FDA has approved AstraZeneca's new breast cancer pill, Etcamah (camizestrant), for use in combination with other medicines for patients with a geneticall

AstraZeneca has halted a stage 2 drug trial for its lung cancer treatment, volrustomig, following a previous decision to stop a heart disease treatment trial a

Investors reportedly thwarted a potential $400 billion megadeal between AstraZeneca and US rival Bristol Myers, which would have marked a significant return to

AstraZeneca's rumored takeover of Bristol Myers Squibb appears to be off, following reports of preliminary talks and a subsequent denial of ongoing discussions.

AstraZeneca shares dropped 7% following reports of historic $400 billion merger talks with Bristol Myers Squibb, which have been ongoing for months without a fo

AstraZeneca's shares fell 8.9% amid reports of potential merger talks with US group Bristol Myers Squibb, raising questions about the strategic necessity of suc

The FTSE 100 index closed down by 0.1% at 10,857.70, with mixed stock performance influenced by merger talks involving AstraZeneca.

The article discusses how large pharmaceutical companies like AstraZeneca and Bristol-Myers benefit from their substantial financial resources, enabling them to

AstraZeneca is reportedly in discussions to acquire US rival Bristol Myers Squibb in a deal that could create a pharmaceutical group worth nearly $400bn, making

AstraZeneca is reportedly in discussions for a £300bn mega-merger with a US rival, a move that would create one of the largest deals in the industry and establi

AstraZeneca is reportedly in talks with Bristol Myers Squibb for a potential $400 billion tie-up. Such a deal would create the world's fourth-largest drugmaker

AstraZeneca Plc reportedly explored an acquisition of Bristol Myers Squibb Co., which would create one of the world's largest pharmaceutical companies, though i

Companies are expanding employee health benefits, with AstraZeneca Pharma India introducing a group cancer care policy to supplement existing medical insurance.

Andhra Pradesh has signed an agreement with AstraZeneca to establish a Genomic Solutions Centre in Amaravati. This centre will utilize next-generation sequencin

Andhra Pradesh has partnered with AstraZeneca to establish an integrated precision oncology ecosystem, utilizing AI and advanced genomics to transform cancer ca

AstraZeneca's shares climbed after the company's adjusted earnings per share, excluding certain items, rose 21% to $2.63 in the latest quarter, exceeding analys

AstraZeneca CEO Pascal Soriot urged Western drugmakers to adopt a "Chinese speed" approach to innovation, warning that Europe and the US risk being outpaced in

Oil prices slid as the US and Iran paused fire, while AstraZeneca exceeded profit forecasts due to cancer treatments; additionally, the UK's financial watchdog

AstraZeneca's nerve drug Wainua failed a late-stage heart disease trial, causing investor concern and a slide in the company's share price. The company's future

The FTSE 100 closed down 16.59 points at 10,472.45, primarily held back by a trial setback experienced by AstraZeneca.

AstraZeneca's stock market value has slumped by over £20 billion after its Wainua drug failed to meet a key goal to reduce deaths related to heart disease. The

AstraZeneca's shares declined after its Ionis-partnered drug, Wainua, failed to meet its primary endpoints in a late-stage heart disease trial, not reducing car